• Home
  • The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.

The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.

Author List
van Schaik RH, Kok M, Sweep FC, van Vliet M, van Fessem M, Meijer-van Gelder ME, Seynaeve C, Lindemans J, Wesseling J, Van 't Veer LJ, Span PN, van Laarhoven H, Sleijfer S, Foekens JA, Linn SC, Berns EM
Publication
Pharmacogenomics
Publication ID (Profile URL)
https://researcherprofiles.org/profile/1486102
Publication Year
2011
PubMed ID
21830868
Publication Title
van Schaik RH, Kok M, Sweep FC, van Vliet M, van Fessem M, Meijer-van Gelder ME, Seynaeve C, Lindemans J, Wesseling J, Van 't Veer LJ, Span PN, van Laarhoven H, Sleijfer S, Foekens JA, Linn SC, Berns EM. The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. Pharmacogenomics. 2011 Aug; 12(8):1137-46.